GFACX
Price
$61.91
Change
-$1.33 (-2.10%)
Updated
Sep 6 closing price
NLCCX
Price
$29.50
Change
-$0.71 (-2.35%)
Updated
Sep 6 closing price
Ad is loading...

GFACX vs NLCCX

Header iconGFACX vs NLCCX Comparison
Open Charts GFACX vs NLCCXBanner chart's image
American Funds Growth Fund of Amer C
Price$61.91
Change-$1.33 (-2.10%)
VolumeN/A
CapitalizationN/A
Voya Large-Cap Growth C
Price$29.50
Change-$0.71 (-2.35%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
GFACX vs NLCCX Comparison Chart
Loading...
VS
GFACX vs. NLCCX commentary
Sep 08, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GFACX is a Buy and NLCCX is a Buy.

FUNDAMENTALS
Fundamentals
GFACX has more cash in the bank: 270B vs. NLCCX (705M). GFACX (0.00) and NLCCX (0.00) have matching dividends . GFACX was incepted earlier than NLCCX: GFACX (24 years) vs NLCCX (27 years). NLCCX is a more actively managed with annual turnover of: 55.00 vs. GFACX (31.00). GFACX has a lower initial minimum investment than NLCCX: GFACX (250) vs NLCCX (1000). NLCCX annual gain was more profitable for investors over the last year : 25.95 vs. GFACX (16.44). GFACX return over 5 years is better than : 38.56 vs. NLCCX (-13.64).
GFACXNLCCXGFACX / NLCCX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence24 years27 years-
Gain YTD14.98217.27687%
Front LoadN/AN/A-
Min. Initial Investment250100025%
Min. Initial Investment IRAN/AN/A-
Net Assets270B705M38,298%
Annual Yield % from dividends0.000.00-
Returns for 1 year16.4425.9563%
Returns for 3 years-11.08-34.8632%
Returns for 5 years38.56-13.64-283%
Returns for 10 years42.46-2.36-1,796%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KW11.040.03
+0.27%
Kennedy-Wilson Holdings
CTVA55.11-0.39
-0.70%
Corteva
FIVN29.58-0.24
-0.80%
Five9
VEV0.14N/A
-1.68%
Vicinity Motor Corp
ADAP1.11-0.05
-4.31%
Adaptimmune Therapeutics plc